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Background: Bleeding complications are common and decrease the odds of survival 
in children supported with extracorporeal membrane oxygenation (ECMO). The role of 
platelet dysfunction on ECMO-induced coagulopathy and resultant bleeding complica-
tions is not well understood. The primary objective of this pilot study was to determine 
the incidence and magnitude of platelet dysfunction according to thromboelastography 
(TEG®)–platelet mapping (PM) testing.
Methods: Retrospective chart review of children <18 years old who required ECMO at 
a tertiary level hospital. We collected TEG®–PM and conventional coagulation tests data. 
We also collected demographic, medications, blood products administered, and clinical 
outcome data. We defined severe platelet dysfunction as <50% aggregation in response 
to an agonist.
results: We identified 24 out of 46 children on ECMO, who had TEG®–PM performed 
during the study period. We found the incidence of severe bleeding was 42% and mor-
tality was 54% in our study cohort. In all samples measured, severe qualitative platelet 
dysfunction was more common for adenosine diphosphate (ADP)-mediated aggregation 
(92%) compared to arachidonic acid (AA)-mediated aggregation (75%) (p = 0.001). Also, 
ADP-mediated percent of platelet aggregation was significant lower than AA-mediated 
platelet aggregation [15% (interquartile range, IQR 2.8–48) vs. 49% (IQR 22–82.5), 
p < 0.001]. There was no difference in kaolin-activated heparinase TEG® parameters 
between the bleeding group and the non-bleeding group. Only absolute platelet count 
and TEG®–PM had increased predictive value on receiver operating characteristics anal-
yses for severe bleeding and mortality compared to activated clotting time.
conclusion: We found frequent and severe qualitative platelet dysfunction on TEG®–PM 
testing in children on ECMO. Larger studies are needed to determine if the assessment 
of qualitative platelet function by TEG®–PM can improve prediction of bleeding compli-
cations for children on ECMO.
Keywords: platelet mapping, thromboelastography, ecMO, anticoagulation, platelet dysfunction, heparin, ecMO-
induced coagulopathy
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inTrODUcTiOn
Extracorporeal membrane oxygenation (ECMO) provides life-
saving support to critically ill children with severe respiratory 
or cardiac failure when conventional therapies are inadequate. 
Approximately 2,000 children receive ECMO support every year, 
and the frequency is steadily increasing (1). Children on ECMO 
have high mortality rates between 35 and 50%, and most deaths 
are related to thromboembolic or bleeding complications (1, 2). 
In a recent study, bleeding and thromboembolic complications 
have shown to decrease survival by 24% (2).
Extracorporeal membrane oxygenation-induced coagu-
lopathy (EIC) is a dynamic and complex pathophysiologic state 
of hemostasis, which is not completely understood. EIC results 
from complex interactions between hemostatic, endothelial, and 
immune systems that are perturbed by the ECMO circuit and 
the patient’s underlying illness (3). Anticoagulation is essential 
to keep the ECMO circuit from clotting, but it increases the 
risk of bleeding especially if the underlying EIC is not cor-
rected. Intensive hemostasis monitoring is required to assess the 
underlying EIC and the adequacy of anticoagulation to minimize 
bleeding complications. Activated clotting time (ACT) remains 
the primary test to monitor hemostasis and anticoagulation for 
children on ECMO (4). Many centers have been using additional 
tests including antithrombin (ATIII) activity and anti-factor Xa 
assays to assess the adequacy of anticoagulation (5). Many studies 
have reported a weak predictive value of these tests in a setting of 
worsening EIC (6–12).
Qualitative platelet dysfunction has shown to occur in children 
on ECMO and may play a role in EIC (13–15). Routine moni-
toring of absolute platelet count to guide platelet transfusion is 
frequently done on ECMO, but qualitative platelet function is sel-
dom measured. Few centers have already incorporated functional 
tests, such as viscoelastic assays [thromboelastography (TEG®)/
rotational thromboelastometry (ROTEM)] and platelet function 
assays [platelet aggregometry or TEG®–platelet mapping (TEG®–
PM)] to improve hemostasis monitoring for children on ECMO 
(5). There is limited data regarding the frequency and magnitude 
of abnormalities detected by these measures in the pediatric 
population, what thresholds indicate the need for therapy, and 
what are the treatment goals (4, 16).
In this pilot study, our primary objective was to determine 
the frequency and magnitude of platelet dysfunction according 
to TEG®–PM. The secondary objective was to analyze the ability 
of conventional and functional hemostatic measures to predict 
severe bleeding and mortality. We hypothesized that qualitative 
platelet dysfunction according to TEG®–PM is common and 
severe in children on ECMO, and TEG®–PM measures are a better 
predictor of bleeding complications and mortality in comparison 
to conventional hemostatic measures.
MaTerials anD MeThODs
Patient Population and study Variables
We conducted a retrospective chart review of children <18 years 
of age who received ECMO support from 9/1/2011 to 12/31/2012 
at St. Louis Children’s Hospital in the neonatal (NICU), cardiac 
(CICU), and pediatric intensive care units (PICU). All the patients 
on whom TEG®–PM was performed during ECMO support 
were included in the study cohort. For each of these patients, 
we collected (1) demographics (age, weight, gender, diagnosis, 
type and duration of ECMO support), (2) hemostasis data 
[ACT, prothrombin (PT), activated partial thromboplastin time 
(aPTT), platelet count, fibrinogen, antithrombin activity (ATIII), 
TEG®–PM parameters, blood products transfused within 24  h 
prior to the TEG®–PM sample, and dose of heparin infusion at 
the time of the TEG®–PM sample], (3) medications which may 
affect platelet function including inhaled nitric oxide (iNO), 
milrinone, and H2-blockers given in 24 h prior to the TEG®–PM 
sample, and (4) outcomes data (severe bleeding while on ECMO 
support and death prior to ICU discharge).
Definitions
We defined severe bleeding as intracranial, pulmonary, or gastro-
intestinal bleeding that required >50% decrease of heparin infu-
sion for ≥12 h or >20 cc/kg of packed red blood transfusion in 
24 h. Severe platelet dysfunction was arbitrarily defined as <50% 
platelet aggregation in response to an agonist on TEG®–PM, since 
no standard or well-accepted definition exists.
Thromboelastography with Platelet 
Mapping Testing
Thromboelastography–platelet mapping (TEG® 5000, 
Haemonetics Corporation analyzer system, Braintree, MA, USA) 
is a whole blood viscoelastic assay that has been well described 
in the literature (13, 17). In brief, the maximum clot strength 
(MAThrombin) is measured by a kaolin-activated whole blood sam-
ple treated with citrate. To measure the contribution of fibrin only 
(MAFibrin) in the clot strength, a whole blood heparinized sample 
is used to remove thrombin effect, and Reptilase and Factor 
XIII (Activator F) are added to the sample to generate a fibrin 
cross-linked clot. To measure the contribution to clot strength 
by adenosine diphosphate (ADP) (MAADP) or arachidonic acid 
(AA) (MAAA) platelet surface receptors, Activator F plus ADP or 
AA is added to a whole blood heparinized sample. To calculate 
the percent platelet aggregation, the following formula is used: 
[(MAADP or AA − MAFibrin)/(MAThrombin − MAFibrin) × 100]%.
We had to limit the study period from 9/1/2011 to 12/31/2012 
as new institutional guidelines were put in place beyond this 
period for ECMO hemostasis management. During the study 
period, anticoagulation management and blood products admin-
istration were based on ACT and conventional hemostasis meas-
ures including hemoglobin, fibrinogen, INR, and platelet count 
in accordance to the Extracorporeal Life Support Organization 
(ELSO) guidelines (18). Anti-Xa, ATIII, TEG®, and TEG®–PM 
were performed in individual patients based on risk of bleeding, 
ongoing bleeding, need of blood products, and adequacy of anti-
coagulation assessed by the treating physician. We did not have a 
standardized anticoagulation or transfusion algorithm based on 
anti-Xa, TEG®, and TEG®–PM measures during the study period. 
Few patients had more than five TEG® samples performed during 
the ECMO support. No more than three TEG®–PM samples were 
analyzed per patient to minimize the sampling bias. In patients 
TaBle 1 | indications of ecMO support in the study group.
indication of ecMO number (N = 24)
arDsa 4
 Sepsis                                     2
 RSV b                                       1  
 Cystic fibrosis                          1
Pulmonary hypertension 4
congenital diaphragmatic hernia 2
Myocarditis/dilated cardiomyopathy 3
Postoperative 11
 Heart transplant                      3
 Single ventricular                     3
 AVCc defect                             1
 Pulmonary stenosis                 1
 Aortic valve replacement          1
 Heart lung transplant               1
 Lung transplant                       1
aAcute respiratory distress syndrome.
bRespiratory syncytial virus.
cAtrioventricular canal defect.
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who had more than three TEG®–PM performed, we only included 
the first sample, the last sample, and the sample collected in 24 h 
prior to a severe bleeding event or at the midpoint of the time 
on ECMO support for the analysis. One investigator was blinded 
to all results when TEG®–PM samples were chosen for analysis 
for patients with more than three samples drawn. To determine 
the association of ADP- or AA-mediated platelet aggregation and 
severe bleeding, only blood samples taken for TEG®–PM and 
conventional hemostatic tests prior to the severe bleeding event 
were analyzed. For mortality prediction, we analyzed all blood 
samples in non-survival and compared with all samples taken 
prior to coming off the ECMO support in survivors.
statistics
The primary objective of this pilot study was to determine the 
frequency and magnitude of platelet dysfunction. Our secondary 
objective was to compare the ability of TEG®–PM and conven-
tional coagulation measures to predict both severe bleeding 
complications and mortality. To determine normality, we used 
histograms to compare the sample data to a normal probability 
curve and also applied Shapiro–Wilk test of normality. Data are 
presented as median and interquartile range (IQR). We applied 
Mann–Whitney U tests to non-normally distributed data and used 
Z value to determine effect size. We used Spearman’s rank correla-
tion coefficient to test the correlation between platelet count and 
ADP- or AA-mediated platelet aggregation. We used forced entry 
forward stepwise logistic regression model to estimate predictive 
models of bleeding and mortality. We performed receiver operating 
characteristic (ROC) curve analyses to determine area under the 
curve (AUC) and its 95% confidence interval of both conventional 
and functional coagulation parameters to predict severe bleeding 
complications and mortality. The analyses were performed by 
using IBM® and SPSS® version 21. The Institutional Review Board 
of Washington University in St. Louis approved this study.
resUlTs
We identified 24 out of 46 consecutive children supported on 
ECMO for various indications, who had TEG®–PM performed 
during the study period from 9/1/2011 to 12/31/2012 (Table 1). 
A total of 57 TEG®–PM samples were analyzed from these 24 
patients with a median (IQR) of 2 (1–3) samples per patient. 
Patients had a median age of 9 (1–70) months and had received 
ECMO support for a median of 8 (6–10) days. Eighteen (75%) 
patients received venoarterial (VA)-ECMO and 6 (25%) patients 
received venovenous (VV)-ECMO support. Severe bleeding 
occurred in 10 (42%) patients and 13 (54%) patients died before 
ICU discharge. All patients were on unfractionated heparin 
infusions with a median dose of 40 (IQR 30–50) units/kg/h at 
the time TEG®–PM samples were drawn. 79% (19) of patients 
were receiving ranitidine, 50% (12) iNO, and 46% (11) milrinone 
24 h before at least one of the TEG®–PM samples. None of these 
patients received direct antiplatelet or antifibrinolytic agents.
In all samples measured, severe platelet dysfunction (<50% 
aggregation in a response to an agonist) was more common for 
ADP-mediated aggregation (92%) compared to AA-mediated 
aggregation (75%) (p = 0.001). ADP-mediated percent of platelet 
aggregation was lower when compared to AA-mediated platelet 
aggregation [15% (IQR 2.8–48) vs. 49% (IQR 22–82.5), p < 0.001]. 
Platelet count had statistically significant but weak correlation 
with AA-mediated PA (r2 = 0.24, p = 0.001) and no correlation 
with ADP-mediated aggregation (r2 = 0.03, p = 0.2) (Figure 1). 
When analyzed individually, the use of the following medications 
within 24  h of sampling were not significantly associated with 
ADP-mediated aggregation: iNO vs. no iNO [12% (3–26) vs. 22% 
(2–50) (p = 0.44)], milrinone vs. no milrinone [25.7% (4–53) vs. 
9.3% (1.7–44) (p = 0.14)], and ranitidine vs. no ranitidine [19.8% 
(5–48) vs. 3.2% (1–47) (p = 0.07)].
Univariate analysis revealed that reduced AA-mediated aggre-
gation was associated with severe bleeding and reduced ADP-
mediated aggregation was associated with mortality (Tables  2 
and 3). On the multivariable logistics forced entry of ACT, ADP-
mediated aggregation, AA-mediated platelet aggregation, and 
platelet count in a forward stepwise model for severe bleeding and 
mortality, only low platelet count was associated with increased 
odds of mortality (odds ratio 0.983, CI 0.968–0.999, p = 0.04).
Prediction of severe bleeding based on ROC curves indicated 
that the AUC and 95% Confidence interval (95% CI) for the ACT 
was lowest at 0.56 (0.39–0.75, p = 0.42) and platelet count was 
0.61 (0.45–0.78, p = 0.16). The AUC for ADP-mediated platelet 
aggregation 0.64 (0.48–0.79, p = 0.11) and AA-mediated platelet 
aggregation 0.68 (0.53–0.83, *p = 0.03) (Figure 2). Prediction of 
mortality based on ROC revealed that the AUC for ACT (0.51, 
0.35–0.67, p = 0.9) was the lowest compared to quantitative plate-
let count (0.73, 0.59–0.86, *p =  0.004) and qualitative markers 
of platelet function [ADP-mediated platelet aggregation (0.67, 
0.52–0.8, *p = 0.03) and AA-mediated platelet aggregation (0.65, 
0.50–0.80, p = 0.06)] (Figure 3).
DiscUssiOn
To the best of our knowledge, this study is the first to report 
the frequency and magnitude of qualitative platelet function 
TaBle 2 | comparison of clinical and coagulation variables between no bleeding and severe bleeding group.
Parameter no severe bleedingc (n = 14) severe bleedingc (n = 10) p-Value effect size r value
clinical variables
Age (months) 9 (0.8–12) 48 (2.7–90) 0.40 −0.17
Female gender [n (%)] 9 (64) 5 (50) 0.57 0.10
ECMO VA [n (%)] 10 (71) 9 (90) 0.17 0.24
Number of TEG samples per patient 2 (1–3) 2 (1–3) 0.9 –
Duration of ECMO support (days) 7 (6–10) 8 (5–9) 0.99 −0.002
Heparin dose (U/kg/h) 40 (30–50) 30 (20–48) 0.04* −0.42
Survival [n (%)] 10 (72%) 3 (30%) 0.003* 0.41
Medicationsa
iNO 6 (43%) 6 (60%) 0.16 –
Milrinone 6 (43%) 5 (50%) 0.78 –
Ranitidine 10 (71%) 9 (90%) 0.27 –
conventional coagulation tests
INR 1.29 (1.11–1.63) 1.33 (1.19–1.62) 0.20 −0.26
aPTT (s) 150 (119–150) 140 (87–150) 0.43 −0.18
ACT (s) 186 (166–196) 185 (164–198) 0.43 −0.16
Platelet count × 1000 per cumm 118 (80–144) 88 (76–120) 0.11 −0.32
Fibrinogen (mg/dl) 222 (192–358) 256 (201–346) 0.58 −0.03
Antithrombin activity (%) 44 (25–73) 40 (14–86) 0.80
Teg®–PM parameters
Reaction time 6.3 (5.4–8.1) 6.9 (6.3–8.5) 0.34 −0.20
K time 2 (1.7–2.7) 2.2 (1.5–2.7) 0.90 −0.02
Maximum amplitude (MA) 57 (51–62) 57 (54.3–62) 0.39 −0.18
Percent lysis at 30 min 0 (0–1) 0 (0.1) 0.70 −0.07
ADP-mediated platelet aggregation 26.7 (2.9–67.7) 9.3 (2.25–23.3) 0.09 −0.34
AA-mediated platelet aggregation 63.4 (41.5–95.7) 40 (14.2–67.5) 0.03* −0.45
Blood products transfusedb
pRBC transfusion (mL/kg) 9 (0–20) 20 (0–30) 0.10 −0.34
PC transfusion (mL/kg) 0 (0–15) 8 (0–17.5) 0.86 −0.03
FFP transfusion (mL/kg) 0 (0–15) 4 (0–15) 0.72 −0.07
aMedication prescribed within 24 h prior to the TEG–PM sample drawn.
bBlood product transfused within 24 h prior to the TEG–PM sample drawn.
cData are represented as median (interquartile range) or number (percentage) as applicable.
*p < 0.05 considered significant.
FigUre 1 | (a,B) Correlation of platelet aggregation and platelet count.
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TaBle 3 | comparison of clinical and coagulation variables between survival and non-survival group.
Parameter survivalb (n = 13) non-survivalb (n = 11) p-Value effect size r value
clinical variables
Age (months) 9 (7–66) 4 (0.6–70) 0.49 −0.15
Female gender [n (%)] 7 (54) 6 (54) 0.79 0.06
ECMO VA [n (%)] 8 (62) 10 (90) 0.02* 0.32
Number of TEG samples per patient 2 (1–3) 2 (1–3) 0.9 –
Duration of ECMO support (days) 7 (5–10) 9 (7–12) 0.14 −0.33
Heparin dose (U/kg/h) 40 (30–45) 40 (30–40) 0.66 −0.10
conventional coagulation tests
INR 1.29 (1–1.48) 1.36 (1.17–1.63) 0.14 −0.32
aPTT (s) 150 (112–150) 119 (74–150) 0.16 −0.31
ACT (s) 186 (179–196) 183 (172–199) 0.86 −0.04
Platelet count × 1000 per cumm 124 (92–151) 85 (71–112) 0.002* −0.67
Fibrinogen (mg/dl) 238 (210–331) 273 (192–396) 0.76 −0.07
Antithrombin activity (%) 72 (35–80) 36 (17–72) 0.09 –
Teg®–PM parameters
Reaction time 6.6 (5.4–8) 6.7 (5.7–7.6) 0.92 −0.02
K time 2 (1.7–2.4) 2 (1.5–2.7) 0.87 −0.03
Maximum amplitude (MA) 57 (52–62) 58 (54–62) 0.80 −0.06
Percent lysis at 30 min 0 (0–1) 0 (0–1) 0.56 −0.13
ADP-mediated platelet aggregation 26 (7–65) 5 (1–43) 0.03* −0.50
AA-mediated platelet aggregation 74 (22–96) 41 (20–66) 0.05 −0.44
Blood products transfuseda
pRBC transfusion (mL/kg) 10 (0–24) 10 (10–23) 0.92 −0.02
PC transfusion (mL/kg) 0 (0–11.5) 10 (0–15) 0.04* −0.44
FFP transfusion (mL/kg) 0 (0–10) 10 (0–15) 0.04* −0.45
aThe amount of blood product transfused within 24 h prior to the TEG–PM sample drawn.
bData are represented as median (interquartile range) or number (percentage) as applicable.
*p < 0.05 considered significant.
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according to TEG®–PM for children on ECMO. We found fre-
quent (more than 75% of patients) and severe qualitative platelet 
dysfunction on TEG®–PM in our patient cohort. The platelet 
dysfunction found on TEG®–PM measures in our patient cohort 
was more pronounced compared to the routine TEG®–PM 
evaluation of healthy adults and children with congenital heart 
defect before cardiopulmonary bypass (CPB) (13, 19). The quali-
tative platelet dysfunction was more common and pronounced to 
ADP-mediated aggregation compared to AA-mediated aggrega-
tion. ADP is stored in dense granules and released upon platelet 
activation. The higher incidence of decrease in ADP-mediated 
platelet aggregation in our cohort may be related to weak agonist 
action of ADP and possible depletion of the stored ADP in the 
circulating platelets. Despite severe qualitative platelet dysfunc-
tion on TEG®–PM measures, we found that the maximum 
amplitude (MA), a surrogate of qualitative platelet function on 
kaolin-activated heparinase TEG® measures, was at the lower 
end of normal range of healthy children in our cohort (20). 
One possible explanation for this observation is a compensa-
tory supranormal fibrinogen response via glycoprotein IIb/
IIIa-mediated platelet aggregation and thrombin response via 
protease-activated receptor (PAR)-mediated platelet aggrega-
tion to overcome decrease in ADP- and AA-mediated platelet 
aggregation (21, 22). Also, we found that R time, K time, and 
Lysis at 30 min on kaolin-activated heparinase TEG® were within 
normal range for age in our cohort (20). In this small pilot study, 
platelet count and TEG®–PM measures were a better predictor 
of severe bleeding and mortality.
Qualitative platelet dysfunction has been described by using 
various assays in children requiring CPB or ECMO support 
(13–15). Chueng et al. have reported a time-dependent decrease 
in platelet aggregation measured by using whole blood platelet-
ionized calcium lumi-aggregometer, despite repeated platelet 
transfusions to maintain platelet counts >100 × 103/mm3 dur-
ing ECMO support (14). Robinson et al. have shown decreased 
platelet aggregation by whole blood platelet lumi-aggregometry 
in response to collagen, ADP, and ristocetin stimulation within 
15 min of cannulation for ECMO (15). They have also observed 
persistent platelet dysfunction even after platelet transfusions in 
their cohort (15). Weitzel et al. have reported impaired platelet 
aggregation in response to collagen, ADP, and AA by TEG®–PM 
measures in children with congenital heart defect requiring CPB 
(13). They found that TEG®–PM measures had sensitivity of 83% 
and specificity of 68% in predicting postoperative bleeding (13). 
Nair et al. have reported 50–72% incidence of platelet dysfunc-
tion in adult patients on ECMO by using Multiplate® analyzer 
for ADP and ristocetin (23). Many medications, including iNO, 
milrinone, H2 receptor blockers, prostaglandins, sildenafil, 
and antiplatelet agents, which are frequently used in patients 
on ECMO can alter qualitative platelet dysfunction (24–27). 
Limited experimental and clinical data studying the effect of 
these medications on qualitative platelet function in children on 
FigUre 2 | receiver operator curve analyses for hemostatic 
parameters to predict severe bleeding. On ROC analyses (n = 24), we 
found that the AUC for ACT was lowest at 0.56 (0.39–0.75, p = 0.42) and 
platelet count was 0.61 (0.45–0.78, p = 0.16). The AUC for ADP-mediated 
platelet aggregation 0.64 (0.48–0.79, p = 0.11) and AA-mediated platelet 
aggregation 0.68 (0.53–0.83, *p = 0.03).*p < 0.05 considered significant.
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ECMO are present (28–30). There was no significant association 
between the use of iNO, milrinone, and ranitidine, and ADP-
mediated platelet aggregation in our cohort. This observation 
might be due to the high incidence and magnitude of platelet 
dysfunction on ADP-mediated aggregation and limited power 
to detect any difference in our cohort. It is difficult to make any 
comparison between the studies we discussed as most of these, 
including ours, are limited by sample size, heterogeneous study 
population, the timing of sampling, and different tests being 
used to measure the qualitative platelet function. These studies 
suggest frequent qualitative platelet dysfunction in children on 
ECMO, which is independent of absolute platelet count. The 
evaluation of qualitative platelet dysfunction by newer point-
of-care platelet function assays may have a potential to enhance 
the hemostasis monitoring in children on ECMO. This can be 
challenging due to lack of an established gold standard to com-
pare newer point-of-care platelet function assays and limited 
clinical experience and validation of these assays in children on 
ECMO (31, 32).
ECMO-induced coagulopathy is a dynamic pathophysi-
ologic state of hemostasis that results from complex alterations 
and interactions of coagulation, fibrinolysis, platelets, endothe-
lium and immune systems (3, 33, 34). Many factors contribute 
to EIC including the ECMO circuit, the patient’s underlying 
illness, anticoagulation agents, medications, and blood prod-
ucts administration (3, 34, 35). These factors restrict the ability 
of any particular single coagulation test to accurately identify 
bleeding risk; hence, our ability to treat patients at risk of EIC 
and resultant persistently high bleeding and thromboembolic 
complications rate in children on ECMO (2). Many centers 
have started incorporating multiple tests including viscoelastic 
(TEG®/ROTEM®) and platelet function assays (TEG®–PM 
and Impedance aggregometry) in the hemostasis evaluation 
to be able to improve the identification of patients at risk of 
EIC (3, 5). Use of these assays in adults undergoing CPB or 
with major trauma has shown to improve outcome, minimize 
blood product transfusion, and reduce the cost of treatment 
(36, 37). There are limited studies on efficacy and threshold 
parameters for these assays in for children on ECMO (38–40). 
Interestingly, we found that kaolin-activated heparinase TEG® 
measures (reflective of the underlying hemostasis potential) 
were within normal range for age and also comparable between 
the bleeding and the non-bleeding patients or the surviving 
and the non-surviving. These observations may be due to 
the correction of TEG® measures by frequent blood products 
administration and/or poor sensitivity of TEG® measures to 
detect the EIC related to endothelial and qualitative platelet 
FigUre 3 | receiver operator curve analyses for hemostatic 
parameters to predict mortality. On ROC analyses (n = 24), we found that 
the AUC for ACT (0.51, 0.35–0.67, p = 0.9) was the lowest compared to 
quantitative platelet count (0.73, 0.59–0.86, *p = 0.004) and TEG®–PM 
parameters of qualitative platelet function [ADP-mediated platelet aggregation 
(0.67, 0.52–0.8, *p = 0.03) and AA-mediated platelet aggregation (0.65, 
0.50–0.80, p = 0.06)]. *p < 0.05 considered significant.
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